Healthcare of Ontario Pension Plan Trust Fund Sells 838,699 Shares of Taysha Gene Therapies, Inc. $TSHA

Healthcare of Ontario Pension Plan Trust Fund trimmed its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 22.5% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 2,883,301 shares of the company’s stock after selling 838,699 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Taysha Gene Therapies were worth $12,888,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its position in shares of Taysha Gene Therapies by 141.5% in the first quarter. Renaissance Technologies LLC now owns 413,203 shares of the company’s stock worth $1,847,000 after buying an additional 242,103 shares during the last quarter. Sei Investments Co. increased its holdings in shares of Taysha Gene Therapies by 7.6% during the 1st quarter. Sei Investments Co. now owns 51,472 shares of the company’s stock valued at $230,000 after acquiring an additional 3,614 shares during the last quarter. Cetera Investment Advisers increased its holdings in shares of Taysha Gene Therapies by 34.5% during the 1st quarter. Cetera Investment Advisers now owns 28,450 shares of the company’s stock valued at $127,000 after acquiring an additional 7,296 shares during the last quarter. Militia Capital Management LLC bought a new position in shares of Taysha Gene Therapies in the 1st quarter valued at approximately $208,000. Finally, Principal Financial Group Inc. raised its stake in shares of Taysha Gene Therapies by 26.2% in the 1st quarter. Principal Financial Group Inc. now owns 16,185 shares of the company’s stock valued at $72,000 after acquiring an additional 3,362 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA opened at $5.54 on Tuesday. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -14.58 and a beta of 1.17. The business has a 50 day moving average price of $5.97 and a 200 day moving average price of $5.37. The company has a quick ratio of 14.04, a current ratio of 14.04 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies, Inc. has a twelve month low of $2.54 and a twelve month high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Research analysts predict that Taysha Gene Therapies, Inc. will post -0.49 earnings per share for the current year.

Insider Activity

In related news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the transaction, the insider owned 936,410 shares of the company’s stock, valued at approximately $5,843,198.40. The trade was a 17.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on TSHA shares. Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a research report on Tuesday, June 23rd. Citizens Jmp reissued a “market outperform” rating and issued a $11.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, July 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Wednesday, June 24th. Wall Street Zen downgraded shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Robert W. Baird raised their target price on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of “Buy” and an average price target of $12.77.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.